Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

3925 - Clinical implication of PDL1 expression and TILs in male breast cancer: More Hype or New Hope? Results from the UMBREAC trial (NCT03240510)

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Topics

Translational Research

Tumour Site

Breast Cancer

Presenters

Syrine Abdeljaoued

Citation

Annals of Oncology (2018) 29 (suppl_8): viii400-viii441. 10.1093/annonc/mdy288

Authors

S. Abdeljaoued1, I. Bettaieb1, A. Goucha1, O. Adouni1, H. El Mokh1, H. Bouzaiene2, J. Ben Hassouna2, H. Boussen3, K. Rahal2, A. Gamoudi1

Author affiliations

  • 1 Immuno-histo-cytology, Institut Salah Azaïz, 1006 - Tunis/TN
  • 2 Surgical oncology, Institut Salah Azaïz, 1006 - Tunis/TN
  • 3 Department Of Medical Oncology, Hopital Abderrahman Mami, 2000 - Ariana/TN
More

Resources

Abstract 3925

Background

Whether PDL1 or TILs have any indication for prognosis in male breast cancer (MBC) patients remains unknown. In this study, we investigated the relationship between the expression and degree of PDL1 and TILs and evaluated the prognostic value of these factors in MBC.

Methods

We retrospectively identified 150 MBC patients diagnosed between 2003 and 2013 at Salah Azaïz Cancer Institute. PDL1, Stromal (str) CD8+ and CD4+ TILs were evaluated immunohistochemically. TILs levels were evaluated following 2014 International TILs Working Group guidelines.

Results

Fifty three percent of MBC patients had low str-TILs and 47% had moderate str-TILs. No lymphocyte predominant breast cancer was identified. Only 12% of MBC patients had high str-CD8+TILs and 11% had high str-CD4+TILs. TNBC subtype and HER2 enriched tumors had higher median levels of str-CD8+TILs, str-CD4+ TILs and str-TILs at diagnosis. On univariate analysis, higher levels of str-CD8+TILs, str-CD4+ TILs and str-TILs were associated with better OS (p = 0.035, p = 0.043 and p = 0.040 respectively). Multivariate analysis identified str-CD8+ TILs and str-TILs as independent prognostic factors for OS ([HR = 0.851 (0.706-0.997), p = 0.000] and [HR = 0.69 (0.43-0.96), p = 0.045] respectively). High expression of PD-L1 was observed in 64.5% of MBC samples. Patients with high PD-L1 expression had significantly shorter overall survival (OS) than patients with low expression (p = 0.002, hazard ratio HR = 5 [2.624 –10.642]). Multivariate analysis identified PD-L1 as independent prognostic factor for OS (p < 0.001, HR = 0.775 [0.680–0.870]).

Conclusions

PD-L1 expression, Str-CD8+ T cells and str-TILs represents promising novel biomarkers with prognostic significance in MBC. Thus, successful inclusion of these markers in prognostic clinical models is becoming a realistic hope in MBC.

Clinical trial identification

NCT03240510.

Legal entity responsible for the study

Institut Salah Azaïz.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.